Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Doxorubicin and Paclitaxel-Loaded Nanoparticle Bone Cement for the Treatment of Metastatic Spine Disease
FY 2020-21
Summary
In advanced stage cancers, metastasis to the bones is common, that is, when the original cancer spreads to the bones. Among the bones, the spine is the most common site where metastases occur. The primary cancers responsible are mainly breast, prostate, lung, and kidney cancers. Spinal metastases cause severe pain, impair mobility, lead to paralysis, increase the risk of fractures, and significantly reduce quality of life. Only 10-20% of patients with spinal metastases survive 2 years beyond the diagnosis. When cancer cells migrate to the spine, they cause bone degeneration. Current medical therapy involves drugs to prevent bone loss, and chemotherapy to treat the cancer. The problem is that chemotherapy drugs are often given systemically through an intravenous route, and have significant negative side effects. Surgical treatment involves removing the cancerous tumor and using bone cement to fill the void created by the resection. The problem with this technique is that bone cement is not bioactive and it does not lead to adequate healing of the bone. Additionally, some cancer cells remain hidden and can be the source for the recurrence of the tumors. Doxorubicin and paclitaxel are two commonly used anticancer drugs. They are administered intravenously. Doxorubicin can cause heart damage, while paclitaxel can lead to nerve degeneration. Delivering these drugs locally at the cancer site would bypass these negative side effects. Since bone cement is used to fill the void created by surgery, loading these drugs into the cement would provide a local and sustained release of these drugs to treat the cancer and prevent recurrence. This research projects aims to develop such a bone cement and test it in rats to determine its viability as a treatment option for cancer patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449499
Name
Siddique Ateeque
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Doxorubicin and Paclitaxel-Loaded Nanoparticle Bone Cement for the Treatment of Metastatic Spine Disease
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Animal Model; Bone Cancer; Bone Cement; Doxorubicin; Drug Delivery; Local Delivery; Nanoparticles; Orthopedic Surgery; Paclitaxel; Spinal Metastases
Abstract
In advanced stage cancers, metastasis to the bones is common, that is, when the original cancer spreads to the bones. Among the bones, the spine is the most common site where metastases occur. The primary cancers responsible are mainly breast, prostate, lung, and kidney cancers. Spinal metastases cause severe pain, impair mobility, lead to paralysis, increase the risk of fractures, and significantly reduce quality of life. Only 10-20% of patients with spinal metastases survive 2 years beyond the diagnosis. When cancer cells migrate to the spine, they cause bone degeneration. Current medical therapy involves drugs to prevent bone loss, and chemotherapy to treat the cancer. The problem is that chemotherapy drugs are often given systemically through an intravenous route, and have significant negative side effects. Surgical treatment involves removing the cancerous tumor and using bone cement to fill the void created by the resection. The problem with this technique is that bone cement is not bioactive and it does not lead to adequate healing of the bone. Additionally, some cancer cells remain hidden and can be the source for the recurrence of the tumors. Doxorubicin and paclitaxel are two commonly used anticancer drugs. They are administered intravenously. Doxorubicin can cause heart damage, while paclitaxel can lead to nerve degeneration. Delivering these drugs locally at the cancer site would bypass these negative side effects. Since bone cement is used to fill the void created by surgery, loading these drugs into the cement would provide a local and sustained release of these drugs to treat the cancer and prevent recurrence. This research projects aims to develop such a bone cement and test it in rats to determine its viability as a treatment option for cancer patients.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Siddique, Ateeque
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~